Virtual Man Inc.
Virtual Man speeds preclinical drug discovery by predicting experimental results and identifying compounds likely to succeed or fail. The company offers a B2B AI platform (ADDD) for in‑silico testing and multi-parameter compound optimization using machine learning, auto-feature-extraction and graph convolutional neural networks with explainable AI outputs. Core capabilities include ADMET/PK prediction, automated compound optimization, and customized model development for pharmaceutical clients, delivered via pay-per-use or tiered services. Virtual Man primarily serves pharmaceutical and drug-development teams to reduce preclinical failures and shorten development timelines.
Virtual Man Inc.
Virtual Man speeds preclinical drug discovery by predicting experimental results and identifying compounds likely to succeed or fail. The company offers a B2B AI platform (ADDD) for in‑silico testing and multi-parameter compound optimization using machine learning, auto-feature-extraction and graph convolutional neural networks with explainable AI outputs. Core capabilities include ADMET/PK prediction, automated compound optimization, and customized model development for pharmaceutical clients, delivered via pay-per-use or tiered services. Virtual Man primarily serves pharmaceutical and drug-development teams to reduce preclinical failures and shorten development timelines.